Elevated fluconazole minimum inhibitory concentrations (MICs) are more frequently observed in Cryptococcus gattii compared to C. neoformans isolates; however, the development of in vivo resistance and the molecular mechanisms responsible have not been reported for this species. We report a case of Cryptococcus gattii (molecular type VGIII) that developed reduced susceptibility to fluconazole during therapy and delineate the molecular mechanisms responsible. Multilocus sequence typing and quantitative DNA analysis of the pre-and post-treatment isolates was performed using well-characterized methods. Pre-and post-treatment clinical isolates were confirmed isogenic, and no differences in ERG11 or PDR11 sequences were found. qPCR found an overexpression of ERG11 and the efflux pump PDR11 in the resistant isolate compared to the isolate collected prior to initiation of antifungal therapy. Reversion to wild-type susceptibility was observed when maintained in antifungal-free media confirming the in vivo development of heteroresistance. The in vivo development of heteroresistance to fluconazole in our patient with C. gattii is secondary to overexpression of the efflux pump PDR11 and the drug target ERG11. Additional work in other clinical isolates with elevated fluconazole MICs is warranted to evaluate the frequency of heteroresistance versus point mutations as a cause of resistance.
Introduction
The triazoles, including fluconazole, are first-line therapy for mild to moderate cryptococcal infections due to their proven efficacy, the infrequency of adverse effects, and favorable drug interaction profiles.
1,2 Collaborative multisite susceptibility studies have shown in vitro resistance in Cryptococcus spp. is uncommon; 3 however, reduced susceptibility to triazoles following clinical use has been reported. [4] [5] [6] [7] [8] [9] [10] [11] [12] The molecular mechanisms behind triazole resistance in C. neoformans have demonstrated resistance most commonly occurs from an upregulation or modification of the target enzyme, reduced access of the drug to the target, or some combination of these mechanisms. 3 Point mutations within the gene (ERG11) encoding for the target enzyme, 14-α-demethylase, have been identified although these are rare with only three prior reports describing this event as a cause of resistance. [13] [14] [15] The overexpression of ERG11 or a change in ERG11 copy number appear to be a more common mechanism. 16 Similarly, efflux of azole antifungal agents out of the cell via multidrug efflux transporters (AFR1 in C. neoformans) has also been identified to play a significant role in reduced triazole susceptibility. 17 The increased expression of ERG11 and efflux pumps in Cryptococcus has been attributed to heteroresistance whereby transient duplications of whole chromosomes carrying genes relevant for azole resistance develop in response to drug stress. 18 The in vivo development of heteroresistance has been described in a mouse model of C. neoformans infection but has not been observed during the clinical care of patients with C. gattii. Recent work has improved our understanding of the mechanisms responsible for elevated fluconazole MICs in C. gattii, including the role of the efflux pump PDR11 in triazole resistance although its role in the in vivo development of resistance has not been previously described. 19 Here we describe for the first time a case of invasive cryptococcosis caused by C. gattii that developed in vivo resistance to fluconazole following prolonged therapy and performed an assessment of the molecular mechanisms that are responsible for the phenotypic differences observed between pre-and post-treatment isolates.
Case
A 3-year old female neutered domestic longhair cat from Angels Camp, California, was evaluated at the Veterinary Medical Teaching Hospital at the University of CaliforniaDavis for a 1-month history of sneezing and intermittent open-mouthed breathing. On examination, the cat's right nare was completely occluded by a flesh-colored mass. Cy- 20 on a C. gattii isolate (JS97) recovered from a nasal swab specimen at the time of relapse demonstrated reduced fluconazole susceptibility (MIC 256 μg/ml at 48 and 72 hours) compared to the isolate (JS75; fluconazole MIC 0.5 μg/ml) recovered from a nasal swab specimen at the time of initial diagnosis ( Table 1 ). The owners were offered additional therapeutic options but declined due to financial constraints. The patient was then lost to follow-up.
Materials and methods
Multilocus sequence typing (MLST) was performed using seven unlinked genetic loci with previously described methods and primers. 21 Conserved regions 400 bp up-and downstream from the ERG11, and PDR11 genes were identified within the C. gattii genome sequences of previously sequenced isolates R265 and WM276 (GenBank Accession numbers JF965442 and JF965444, respectively) and sequence alignment performed using Geneious R6 (Auckland, NZ). Primers were designed 35 bp upstream of the ATG initiation codon and 35 bp downstream of the termination codon, and the other primer pair was designed to complete the full (internal) sequence of the gene. Primers were synthesized by Integrated DNA Technologies, Inc (Coralville, IA). Genomic DNA was extracted using a commercially available kit (MasterPure Yeast DNA Purification Kit, Epicentre
Biotechnologies, Madison, WI). RNA was extracted using the RNeasy mini kit (Qiagen). PCR reactions were performed as previously described (Table 2) . 13 The Quantitect Reverse transcription kit (Qiagen) was used for cDNA synthesis following the manufactures directions with the following modifications. For quantitative DNA and mRNA analysis of the ERG11 and PDR11 genes (C. neoformans AFR1 ortholog) qPCR was performed by the UC-Davis core facility (Table 3 ). For each target gene two primers and an internal fluorescent labeled probe (5´end, reporter dye FAM (6-carboxyflourescein), 3´end, quencher dye) was designed using Primer Express software (Applied Biosystems, Foster City, CA). qPCR systems were validated using 2-fold dilutions of cDNA testing positive for the target genes. The dilutions were analyzed in triplicate and a standard curve plotted against the dilutions. The slope of the standard curve was used to calculate amplification efficiencies using the formula E = 10 1/-s -1. To pass validation all efficiencies must be greater than 90%. Copy numbers were compared using standard t-tests between groups. Each qPCR reaction contained 20x primer and probes for the respective qPCR system with a final concentration of 400 nM for each primer and 80 nM for the probe and commercially available PCR mastermix (TaqMan Universal PCR Mastermix, Applied Biosystems) containing 10 mM Tris-HCl (pH 8. Stability of fluconazole resistance in vitro was assessed by taking subclones from each strain suspended in YPD broth and repeatedly transferring 50 μl to 5ml of fresh YPD broth daily and incubated at 30
• C for 24 h as previously described. 17 Subpopulations were periodically tested for continued fluconazole resistance and assessed until reversion to wild-type susceptibility was observed.
Results
MLST confirmed strain isogenicity for isolates JS75 and JS97 and genotype VGIII. Sequences were identical for these two isolates within the URA5, SOD1, CAP59, GPD1, LAC1, PLB1, and IGS1 regions using each of the primer pairs, while differences were observed compared to three other VGIII isolates used as external controls (data not shown). PDR11 and ERG11 copy number were significantly higher in the fluconazole resistant (JS97) isolate compared to that of JS75 (PDR11 increased 2. In vitro development of resistance following serial exposure of the JS75 isolate to fluconazole concentrations occurred after 10 transfers, while reversion of the JS97 isolate to wild type susceptibility was considerably more recalcitrant, requiring 87 transfers on drug-free media.
Discussion
Prior reports have illustrated the potential for triazole resistance to emerge during therapy for cryptococcal infections. [4] [5] [6] [7] [8] [9] [10] [11] [12] These publications have focused exclusively on C. neoformans yet our case demonstrates the emergence of in vivo resistance to fluconazole in C. gattii. Confirmation of strain isogenicity and wild-type sequences within the PDR11 and ERG11 regions suggests the in vivo development of heteroresistance in the isolate after clinical relapse. In C. neoformans resistance has been shown to occur following changes in the affinity of the ERG11 transcript (sterol 14α-demethylase), 13 or target enzyme (Erg11) and multidrug efflux pump (Afr1) upregulation. 22 These changes in gene expression have since been found to be an adaptive mode of azole resistance-termed heteroresistance-whereby C. neoformans develops chromosomal aneuploidy with a resultant increase in ERG11 and AFR1 expression under fluconazole drug pressure and the degree of aneuploidy correlates with the level of fluconazole resistance. 17 In the absence of fluconazole, duplicated copies of chromosomes are lost and following serial passage in drug free media antifungal susceptibility reverts to wild-type. In C. gattii a similar mechanism has been found and is mediated by an upregulation of PDR11 (AFR1 ortholog) 19 and ERG11. In our patient, significantly increased copy numbers of both PDR11 and ERG11 were observed in JS97 compared to JS75, while ERG11 and PDR11 sequences between these isolates were isogenic. Confirmation of upregulation was also confirmed by relative gene copy number in isolates exposed to increasing and decreasing fluconazole concentrations and by significant changes in mRNA expression between isolates. Prior reports have suggested resistant cryptococcal strains may contain a mixed population of cells, with different copy numbers present for different chromosomes, and some chromosomes may have copy numbers above 2N with others present in a single copy. 23 These prior observations are consistent with our qPCR results with non 'whole' numbers suggesting a mixed population. It is noteworthy that the isolates we observed developed resistance to fluconazole only, while other triazoles developed an increase in the MIC from baseline but at levels unlikely to impact patient care; and improvement was initially noted after starting itraconazole therapy. Prior work on heteroresistant C. neoformans isolates has shown those with high-level fluconazole resistance often demonstrate moderate voriconazole resistance (1 μg/ml) and typically no change in itraconazole MICs. 24 We are unaware of similar work in C. gattii isolates. Differences in antifungal skin penetration and half-life may also have played a role in the initial improvement on itraconazole; 25 however, relapses, such as that we observed in our patient, may be more common in isolates with heteroresistance. 26 Varma et al. have previously reported the overall level of heteroresistance to fluconazole in C. gattii strains is significantly higher than those in C. neoformans isolates. 27 These findings suggest factors intrinsic to each species may account for the differing frequencies of the level of heteroresistance to fluconazole. It is unclear what role ecologic factors have played in the development of these divergent species over time 28 although C. neoformans is frequently found in pigeon guano, while C. gattii has not been isolated from this source. 29 Disparate exposure to their respective environmental niches during competition thus may have promoted the higher level of heteroresistance to fluconazole observed in C. gattii isolates.
In conclusion, continued exposure to antimicrobials may be associated with the development of resistance, and we report the first case of C. gattii heteroresistance developing in vivo and define the molecular mechanisms responsible. A heightened suspicion for reduced fluconazole susceptibility as a possible cause of treatment failure in cryptococcosis is needed as the use of these agents continues to increase.
